SCHEMBL2580843

SCHEMBL2580843

CN(Cc1ccc(Cl)cc1Cl)C(CO)c1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 3/20 0.43
CYP2D6 P10635 3/20 0.36
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
ERCC1 P07992 1/20 0.35
ERCC4 Q92889 1/20 0.35
SLC6A3 Q01959 1/20 0.35
MAPK1 P28482 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2578171 0.86 PYCR1 (0.40) PYCR1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL2568820 0.79 PYCR1 (0.42) PYCR1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL2580840 0.76 PYCR1 (0.48) PYCR1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL2568706 0.74 MEN1 (0.42) CYP2D6CYP3A4TDP1SLC6A2SLC6A4
SCHEMBL26675992 0.72 PYCR1 (0.51) PYCR1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL4543601 0.72 AOC3 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2655817 0.72 PYCR1 (0.54) PYCR1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL5644680 0.70 POLB (0.47) PYCR1SLC6A2SLC6A4ERCC1ERCC4
SCHEMBL10915673 0.69 PYCR1 (0.44) PYCR1CYP1A2SLC6A2SLC6A4SLC6A3
SCHEMBL2568818 0.68 HTT (0.49) PYCR1CYP2D6CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2384318-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2011-11-09 EP disclosed
WO-2010078449-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2010-07-08 WO disclosed